Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Spero Therapeutics Inc's Business Segments
Spero Therapeutics Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 0
Regions Reported
-
Spero Therapeutics Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category -
- Collaboration Revenue Related Party100%
Revenue by Product & Service Category -
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Collaboration Revenue Related Party | $ 0 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Spero Therapeutics Inc
Spero Therapeutics Inc. is a biopharmaceutical company that is focused on developing novel therapies for the treatment of bacterial infections. The company is headquartered in Cambridge, Massachusetts and was founded in 2013.
Spero Therapeutics is committed to addressing the growing problem of antibiotic resistance, which has become a major global health concern. The company is dedicated to finding innovative and effective solutions to combat drug-resistant bacterial infections and improve patient outcomes.
One of the key areas of focus for Spero Therapeutics is developing new antibiotics. The company believes that the discovery and development of novel antibiotics is crucial in the fight against drug-resistant bacteria. Spero Therapeutics uses its proprietary platform called SPR720 to identify and develop new compounds with potent antimicrobial activity.
In addition to developing new antibiotics, Spero Therapeutics also works on combination therapies. These therapies involve using multiple drugs in combination to target multiple pathways of bacterial resistance. By targeting multiple mechanisms of resistance, Spero Therapeutics aims to increase the effectiveness of treatment and reduce the development of further resistance.
Spero Therapeutics has a diverse pipeline of drug candidates in various stages of development. Its lead product candidate, Tebipenem HBr (tebipenem pivoxil hydrobromide), is an oral carbapenem antibiotic designed to treat complicated urinary tract infections. The drug has been submitted for regulatory approval in the United States and the European Union.
Another promising candidate in Spero Therapeutics' pipeline is SPR206, a synthetic cyclic peptide agent designed to treat multidrug-resistant Gram-negative infections. SPR206 has shown potent activity against a wide range of Gram-negative bacteria, including those resistant to current antibiotics.
To support its drug development efforts, Spero Therapeutics collaborates with various academic institutions, research organizations, and industry partners. The company also actively seeks funding through government grants, private investments, and partnerships.
Spero Therapeutics is dedicated to making its therapies accessible to patients globally. The company aims to address the unmet medical needs of patients suffering from drug-resistant infections and improve healthcare outcomes.
Overall, Spero Therapeutics Inc. is a biopharmaceutical company dedicated to developing innovative therapies to combat drug-resistant bacterial infections. With a focus on new antibiotics and combination therapies, the company aims to address the critical issue of antibiotic resistance and improve patient outcomes.
Spero Therapeutics is committed to addressing the growing problem of antibiotic resistance, which has become a major global health concern. The company is dedicated to finding innovative and effective solutions to combat drug-resistant bacterial infections and improve patient outcomes.
One of the key areas of focus for Spero Therapeutics is developing new antibiotics. The company believes that the discovery and development of novel antibiotics is crucial in the fight against drug-resistant bacteria. Spero Therapeutics uses its proprietary platform called SPR720 to identify and develop new compounds with potent antimicrobial activity.
In addition to developing new antibiotics, Spero Therapeutics also works on combination therapies. These therapies involve using multiple drugs in combination to target multiple pathways of bacterial resistance. By targeting multiple mechanisms of resistance, Spero Therapeutics aims to increase the effectiveness of treatment and reduce the development of further resistance.
Spero Therapeutics has a diverse pipeline of drug candidates in various stages of development. Its lead product candidate, Tebipenem HBr (tebipenem pivoxil hydrobromide), is an oral carbapenem antibiotic designed to treat complicated urinary tract infections. The drug has been submitted for regulatory approval in the United States and the European Union.
Another promising candidate in Spero Therapeutics' pipeline is SPR206, a synthetic cyclic peptide agent designed to treat multidrug-resistant Gram-negative infections. SPR206 has shown potent activity against a wide range of Gram-negative bacteria, including those resistant to current antibiotics.
To support its drug development efforts, Spero Therapeutics collaborates with various academic institutions, research organizations, and industry partners. The company also actively seeks funding through government grants, private investments, and partnerships.
Spero Therapeutics is dedicated to making its therapies accessible to patients globally. The company aims to address the unmet medical needs of patients suffering from drug-resistant infections and improve healthcare outcomes.
Overall, Spero Therapeutics Inc. is a biopharmaceutical company dedicated to developing innovative therapies to combat drug-resistant bacterial infections. With a focus on new antibiotics and combination therapies, the company aims to address the critical issue of antibiotic resistance and improve patient outcomes.
Spero Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies, especially for treating patients with serious infections caused by multi-drug resistant (MDR) bacteria. Their portfolio primarily focuses on addressing significant unmet medical needs associated with bacterial infections and related conditions.
Segments:
1. Infectious Diseases:
- This segment concentrates primarily on developing treatment options for infections caused by antibiotic-resistant bacteria. The focus is on both Gram-negative and Gram-positive bacterial infections, which are increasingly challenging due to resistance patterns.
2. Hospital Acquired Infections (HAIs):
- Spero targets medications for infections that patients acquire during hospital stays. These infections often involve multidrug-resistant organisms and may complicate treatment due to the patients compromised health.
3. Complicated Urinary Tract Infections (cUTIs):
- The development of therapies aimed at treating cUTIs is a priority within the companys portfolio, particularly in light of increasing resistance to conventional antibiotics in treating these infections.
Products:
1. Tezspire (A monoclonal antibody designed for the treatment of asthma and allergic diseases):
- While primarily associated with AstraZeneca, Spero has been involved in research related initiatives. It is notable as a part of the larger field of monoclonal therapies that offer targeted treatment approaches.
2. SP-304 (an investigational therapeutic):
- This candidate aims at treating infections caused by MDR Gram-negative bacteria. It is designed to show efficacy against resistant strains, focusing on safety and tolerability.
3. SP-635:
- Another investigational product focusing on treating complex S. aureus infections, including both MSSA and MRSA strains, addressing a significant public health concern related to resistant bacterial infections.
Services:
1. Clinical Trial Operations:
- Spero operates extensive clinical programs designed to evaluate the safety and efficacy of their investigational products. They conduct trials that encompass Phase 1, Phase 2, and later-stage clinical trials, collaborating with medical institutions and research sites to gather data on their drugs.
2. Regulatory Affairs:
- The company is engaged in navigating the complex regulatory landscape to obtain approval for their drugs. This involves interaction with the FDA and other global regulatory bodies to ensure compliance and to facilitate the timely review of new therapies.
3. Partnerships and Collaborations:
- Spero Therapeutics actively seeks partnerships with other biopharmaceutical companies and academic institutions to foster innovation, enhance research capabilities, and potentially broaden the development scope of their therapeutics.
4. Research and Development:
- Their R&D services are robust, focusing on innovative drug discovery to identify novel antibiotic mechanisms or combinations that can overcome resistance. This includes both in vitro and in vivo studies.
Conclusion:
Spero Therapeutics Inc. is dedicated to combatting the growing threat of antibiotic-resistant infections through a focused pipeline of investigational medications and robust clinical programs. Their commitment to addressing serious unmet medical needs in infectious diseases is evident in the segments and products they are developing, alongside the services that support their mission of delivering effective therapies for patients suffering from severe bacterial infections.
Segments:
1. Infectious Diseases:
- This segment concentrates primarily on developing treatment options for infections caused by antibiotic-resistant bacteria. The focus is on both Gram-negative and Gram-positive bacterial infections, which are increasingly challenging due to resistance patterns.
2. Hospital Acquired Infections (HAIs):
- Spero targets medications for infections that patients acquire during hospital stays. These infections often involve multidrug-resistant organisms and may complicate treatment due to the patients compromised health.
3. Complicated Urinary Tract Infections (cUTIs):
- The development of therapies aimed at treating cUTIs is a priority within the companys portfolio, particularly in light of increasing resistance to conventional antibiotics in treating these infections.
Products:
1. Tezspire (A monoclonal antibody designed for the treatment of asthma and allergic diseases):
- While primarily associated with AstraZeneca, Spero has been involved in research related initiatives. It is notable as a part of the larger field of monoclonal therapies that offer targeted treatment approaches.
2. SP-304 (an investigational therapeutic):
- This candidate aims at treating infections caused by MDR Gram-negative bacteria. It is designed to show efficacy against resistant strains, focusing on safety and tolerability.
3. SP-635:
- Another investigational product focusing on treating complex S. aureus infections, including both MSSA and MRSA strains, addressing a significant public health concern related to resistant bacterial infections.
Services:
1. Clinical Trial Operations:
- Spero operates extensive clinical programs designed to evaluate the safety and efficacy of their investigational products. They conduct trials that encompass Phase 1, Phase 2, and later-stage clinical trials, collaborating with medical institutions and research sites to gather data on their drugs.
2. Regulatory Affairs:
- The company is engaged in navigating the complex regulatory landscape to obtain approval for their drugs. This involves interaction with the FDA and other global regulatory bodies to ensure compliance and to facilitate the timely review of new therapies.
3. Partnerships and Collaborations:
- Spero Therapeutics actively seeks partnerships with other biopharmaceutical companies and academic institutions to foster innovation, enhance research capabilities, and potentially broaden the development scope of their therapeutics.
4. Research and Development:
- Their R&D services are robust, focusing on innovative drug discovery to identify novel antibiotic mechanisms or combinations that can overcome resistance. This includes both in vitro and in vivo studies.
Conclusion:
Spero Therapeutics Inc. is dedicated to combatting the growing threat of antibiotic-resistant infections through a focused pipeline of investigational medications and robust clinical programs. Their commitment to addressing serious unmet medical needs in infectious diseases is evident in the segments and products they are developing, alongside the services that support their mission of delivering effective therapies for patients suffering from severe bacterial infections.